Background: Current guidelines offer numerous options for initiating therapy in patients with
untreated, advanced stage follicular lymphoma (FL). Selecting among these options that …

Follicular lymphoma (FL) is the second most common lymphoma in the United States and is
characterized by a variable clinical course, disease heterogeneity, and a relapse-and …

Background: Although advanced stage follicular lymphoma (FL) is considered incurable with
standard therapy, and early institution of therapy has not demonstrated benefits over …

Opinion Statement The optimal initial treatment of follicular lymphoma (FL) is not known, and
initial management of patients varies considerably between providers and institutions. The …

Abstract 1798 Rituximab maintenance for the treatment of patients with follicular lymphoma:
systematic review and meta-analysis of randomized trials-2010 update. Liat Vidal, Anat …

E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …

Introduction In their lifetime, patients with follicular lymphoma frequently require multiple
treatments, which have improved their survival over the past few decades. The expected …

Rituximab was approved in France in 2004, following randomized trials that demonstrated
efficacy in newly diagnosed high tumour burden follicular lymphoma (FL). This retrospective …

Phase 2 studies suggest that the monoclonal antibody rituximab may improve the prognosis
of patients with follicular lymphoma (FL) when it is added to chemotherapy. In the current …

Purpose Although rituximab (R) is commonly used for patients with advanced follicular
lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to …